GRI Bio (GRI) Competitors

0.42
+0.01 (+1.82%)
(As of 05/17/2024 08:53 PM ET)

GRI vs. LSDI, BDRX, PBLA, NBSE, INM, PRFX, QLGN, PXMD, ATNF, and SPRC

Should you be buying GRI Bio stock or one of its competitors? The main competitors of GRI Bio include Lucy Scientific Discovery (LSDI), Biodexa Pharmaceuticals (BDRX), Panbela Therapeutics (PBLA), NeuBase Therapeutics (NBSE), InMed Pharmaceuticals (INM), PainReform (PRFX), Qualigen Therapeutics (QLGN), PaxMedica (PXMD), 180 Life Sciences (ATNF), and SciSparc (SPRC). These companies are all part of the "pharmaceutical preparations" industry.

GRI Bio vs.

GRI Bio (NASDAQ:GRI) and Lucy Scientific Discovery (NASDAQ:LSDI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

In the previous week, GRI Bio had 6 more articles in the media than Lucy Scientific Discovery. MarketBeat recorded 8 mentions for GRI Bio and 2 mentions for Lucy Scientific Discovery. Lucy Scientific Discovery's average media sentiment score of 1.02 beat GRI Bio's score of 0.27 indicating that Lucy Scientific Discovery is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GRI Bio
0 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Lucy Scientific Discovery
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Lucy Scientific Discovery has higher revenue and earnings than GRI Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GRI BioN/AN/A-$13.04MN/AN/A
Lucy Scientific Discovery$16.73K154.01-$8.99M-$7.00-0.21

Lucy Scientific Discovery's return on equity of -294.74% beat GRI Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
GRI BioN/A -548.12% -290.50%
Lucy Scientific Discovery N/A -294.74%-137.65%

GRI Bio has a beta of -1.55, indicating that its stock price is 255% less volatile than the S&P 500. Comparatively, Lucy Scientific Discovery has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GRI Bio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Lucy Scientific Discovery
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

34.0% of GRI Bio shares are owned by institutional investors. Comparatively, 72.6% of Lucy Scientific Discovery shares are owned by institutional investors. 3.0% of GRI Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Lucy Scientific Discovery received 1 more outperform votes than GRI Bio when rated by MarketBeat users.

CompanyUnderperformOutperform
GRI BioN/AN/A
Lucy Scientific DiscoveryOutperform Votes
1
100.00%
Underperform Votes
No Votes

Summary

Lucy Scientific Discovery beats GRI Bio on 9 of the 11 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRI vs. The Competition

MetricGRI BioPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.59M$6.80B$5.24B$7.99B
Dividend YieldN/A2.72%44.24%3.91%
P/E RatioN/A10.51103.2115.05
Price / SalesN/A289.142,370.1481.39
Price / CashN/A34.4236.7931.98
Price / Book0.575.795.494.64
Net Income-$13.04M$138.82M$105.95M$217.28M
7 Day Performance2.44%1.45%1.42%2.90%
1 Month Performance-20.44%4.81%4.96%6.66%
1 Year Performance-99.04%-3.83%7.84%9.89%

GRI Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LSDI
Lucy Scientific Discovery
0 of 5 stars
$0.74
+1.4%
N/A-86.5%$1.29M$10,000.00-0.112News Coverage
Gap Up
BDRX
Biodexa Pharmaceuticals
2.0259 of 5 stars
$0.97
+4.3%
$8.00
+729.0%
-92.9%$1.25M$410,000.000.0021Gap Down
PBLA
Panbela Therapeutics
0.8836 of 5 stars
$0.41
+8.0%
$500.00
+123,022.4%
-99.8%$1.41MN/A0.007Analyst Forecast
Analyst Revision
News Coverage
NBSE
NeuBase Therapeutics
0 of 5 stars
$0.38
flat
N/AN/A$1.42MN/A-0.0537Gap Up
INM
InMed Pharmaceuticals
0.1926 of 5 stars
$0.26
flat
N/A-78.8%$1.60M$4.14M0.0013Upcoming Earnings
News Coverage
Gap Up
PRFX
PainReform
0 of 5 stars
$0.82
+5.1%
N/A-86.1%$1.67MN/A0.007Earnings Report
Upcoming Earnings
News Coverage
Gap Down
QLGN
Qualigen Therapeutics
0 of 5 stars
$0.27
-3.6%
N/A-69.7%$1.70M$4.98M0.004Upcoming Earnings
Positive News
Gap Down
PXMD
PaxMedica
1.3207 of 5 stars
$0.23
+9.6%
$3.00
+1,211.2%
-99.0%$1.71MN/A-0.016Earnings Report
Upcoming Earnings
ATNF
180 Life Sciences
0 of 5 stars
$2.02
+4.7%
N/A-92.0%$1.72MN/A0.004Upcoming Earnings
News Coverage
Gap Down
SPRC
SciSparc
0 of 5 stars
$1.25
flat
N/A-92.3%$888,000.00$2.88M0.003Positive News

Related Companies and Tools

This page (NASDAQ:GRI) was last updated on 5/19/2024 by MarketBeat.com Staff

From Our Partners